Aclaris Therapeutics To Host 2025 R&D Day In Midtown, New York On October 14 To Discuss Its Progress In Addressing Therapeutic Gaps In Immuno-Inflammatory Markets

Author: Benzinga Newsdesk | September 30, 2025 06:14am

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it's 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company's progress in addressing therapeutic gaps in immuno-inflammatory markets. To register, please click here.

The event will feature presentations by Aclaris leadership and Zuzana Diamant, MD, PhD, FERS (Pulmonologist and Clinical Pharmacologist affiliated with the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, Netherlands) and Michael C. Cameron, MD, FAAD (Assistant Clinical Professor in the Department of Dermatology at Mount Sinai, New York), who will highlight Aclaris' development of kinase and immune pathway inhibitor franchises addressing therapeutically relevant, validated immune targets, and the markets and gaps the Company seeks to address.

Among the topics that Aclaris leadership will discuss are:

• Aclaris' work in developing uniquely potent small and large molecule product candidates to address significant gaps in important I&I indications
• Perspectives on Aclaris' innovative discovery technology platform, and its progress towards its goal of "drugging the undruggable" by targeting previously inaccessible components of the kinome and multiple pathways
• Insights into the Company's progress with its potential best-in-class ITK inhibition franchise
• More on Aclaris' TSLP franchise, and Aclaris' progress in developing monoclonal and bispecific antibodies against validated targets
• New updates on Aclaris' execution on its ongoing clinical trials and on designing future clinical programs

Posted In: ACRS